KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sabre (SABR) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Sabre (SABR) over the last 13 years, with Q3 2025 value amounting to $20.3 million.

  • Sabre's Capital Expenditures rose 506.97% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.7 million, marking a year-over-year decrease of 589.09%. This contributed to the annual value of $84.1 million for FY2024, which is 374.62% down from last year.
  • Sabre's Capital Expenditures amounted to $20.3 million in Q3 2025, which was up 506.97% from $21.3 million recorded in Q2 2025.
  • Sabre's Capital Expenditures' 5-year high stood at $30.1 million during Q2 2023, with a 5-year trough of $6.4 million in Q1 2021.
  • Its 5-year average for Capital Expenditures is $18.7 million, with a median of $18.8 million in 2023.
  • Per our database at Business Quant, Sabre's Capital Expenditures plummeted by 7737.1% in 2021 and then surged by 17044.29% in 2022.
  • Quarter analysis of 5 years shows Sabre's Capital Expenditures stood at $23.9 million in 2021, then crashed by 32.95% to $16.0 million in 2022, then grew by 17.43% to $18.8 million in 2023, then increased by 2.63% to $19.3 million in 2024, then grew by 4.98% to $20.3 million in 2025.
  • Its Capital Expenditures was $20.3 million in Q3 2025, compared to $21.3 million in Q2 2025 and $17.9 million in Q1 2025.